AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $224.00, giving the company a market capitalization of 395.88B. It carries a P/E multiple of 166.14 and pays a dividend yield of 3.0%.
As of 2026-01-06, AbbVie(ABBV) stock has fluctuated between $219.86 and $224.20. The current price stands at $224.00, placing the stock +1.9% above today's low and -0.1% off the high.
The AbbVie(ABBV)'s current trading volume is 9.15M, compared to an average daily volume of 5.28M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
AbbVie recently entered a global collaboration and license option agreement with China’s Zelgen Pharma for ZG006, granting AbbVie exclusive rights to develop an...
AbbVie pays $6.56 in dividends against only $1.33 in earnings per share due to Humira patent loss. DHS returned 17.6% over the past year but its monthly distri...
If you are wondering whether AbbVie stock still offers value at its current level, this article will walk through how the numbers stack up and what that could m...
Analyst ratings
68%
of 31 ratingsMore ABBV News
Key Points AbbVie has a solid business capable of performing well even in bad times. The company has proven that it can navigate challenges thanks to its inno...
AbbVie ABBV has built a substantial neuroscience franchise. While the segment was initially anchored by Botox Therapeutic and the depression drug Vraylar, its o...